Access the full text.
Sign up today, get DeepDyve free for 14 days.
(2019)
Development , validation and results from the impact of treatment evolution in non - small cell
H. Guan, Y. Sheng, W. Guo, Sheng Han, Luwen Shi (2019)
Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in ChinaAdvances in Therapy, 36
(Cumpston M, Higgins JPT, Churchill R, Chandler J. Cochrane handbook for systematic reviews of interventions version 6.1.0,” 2020. https://training.cochrane.org/handbook/current.)
Cumpston M, Higgins JPT, Churchill R, Chandler J. Cochrane handbook for systematic reviews of interventions version 6.1.0,” 2020. https://training.cochrane.org/handbook/current.Cumpston M, Higgins JPT, Churchill R, Chandler J. Cochrane handbook for systematic reviews of interventions version 6.1.0,” 2020. https://training.cochrane.org/handbook/current., Cumpston M, Higgins JPT, Churchill R, Chandler J. Cochrane handbook for systematic reviews of interventions version 6.1.0,” 2020. https://training.cochrane.org/handbook/current.
Mingxia Wang, Guan Wang, Haiyang Ma, B. Shan (2018)
Crizotinib Versus Chemotherapy on ALK-positive NSCLC: A Systematic Review of Efficacy and Safety.Current cancer drug targets, 19 1
(2014)
Editors BW Stewart and CP Wild
(Eisenhauer EA, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247)
Eisenhauer EA, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247Eisenhauer EA, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247, Eisenhauer EA, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247
(Globocan. New Global Cancer Data. GLOBOCAN 2018, 2018. https://www.uicc.org/news/new-global-cancer-data-globocan-2018.)
Globocan. New Global Cancer Data. GLOBOCAN 2018, 2018. https://www.uicc.org/news/new-global-cancer-data-globocan-2018.Globocan. New Global Cancer Data. GLOBOCAN 2018, 2018. https://www.uicc.org/news/new-global-cancer-data-globocan-2018., Globocan. New Global Cancer Data. GLOBOCAN 2018, 2018. https://www.uicc.org/news/new-global-cancer-data-globocan-2018.
(Khan M, et al. ALK inhibitors in the treatment of ALK positive NSCLC. Front Oncol. 2019. 10.3389/fonc.2018.00557.)
Khan M, et al. ALK inhibitors in the treatment of ALK positive NSCLC. Front Oncol. 2019. 10.3389/fonc.2018.00557.Khan M, et al. ALK inhibitors in the treatment of ALK positive NSCLC. Front Oncol. 2019. 10.3389/fonc.2018.00557., Khan M, et al. ALK inhibitors in the treatment of ALK positive NSCLC. Front Oncol. 2019. 10.3389/fonc.2018.00557.
Hirokazu Watanabe, M. Okada, Yasushi Kaji, M. Satouchi, Yozo Sato, Y. Yamabe, H. Onaya, M. Endo, M. Sone, Y. Arai (2009)
[New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)].Gan to kagaku ryoho. Cancer & chemotherapy, 36 13
Xing Du, Xiaoli Zheng, Pengcheng Wang, Yi Wang (2018)
Efficacy and safety of crizotinib for treatment of ALK-positive NSCLC : a meta-analysis
(Moher D, et al. Evaluation of ASTM standard test method E 2177, 6 retroreflectivity of pavement markings in a condition of 7 wetness. Syst Rev. 2015; 1–9)
Moher D, et al. Evaluation of ASTM standard test method E 2177, 6 retroreflectivity of pavement markings in a condition of 7 wetness. Syst Rev. 2015; 1–9Moher D, et al. Evaluation of ASTM standard test method E 2177, 6 retroreflectivity of pavement markings in a condition of 7 wetness. Syst Rev. 2015; 1–9, Moher D, et al. Evaluation of ASTM standard test method E 2177, 6 retroreflectivity of pavement markings in a condition of 7 wetness. Syst Rev. 2015; 1–9
P. Cortazar, Lijun Zhang, M. Untch, K. Mehta, J. Costantino, N. Wolmark, H. Bonnefoi, D. Cameron, L. Gianni, P. Valagussa, S. Swain, Tatiana Prowell, S. Loibl, L. Wickerham, J. Bogaerts, J. Baselga, C. Perou, G. Blumenthal, J. Blohmer, E. Mamounas, J. Bergh, V. Semiglazov, R. Justice, H. Eidtmann, S. Paik, M. Piccart, R. Sridhara, P. Fasching, L. Slaets, Shenghui Tang, B. Gerber, C. Geyer, R. Pazdur, N. Ditsch, P. Rastogi, W. Eiermann, G. Minckwitz (2014)
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysisThe Lancet, 384
M. Page, Larissa Shamseer, A. Tricco (2018)
Registration of systematic reviews in PROSPERO: 30,000 records and countingSystematic Reviews, 7
(2006)
Cochrane Handbook for Systematic Reviews of Interventions Edited by Julian P. T. Higgins &
(2018)
Crizotinib 200mg and 250mg hard capsules (XalkoriÒ) SMC No 1329/18
(Cohen D. Cancer drugs: high price, uncertain value. BMJ (Clin Res Ed). 2017;359:j4543.)
Cohen D. Cancer drugs: high price, uncertain value. BMJ (Clin Res Ed). 2017;359:j4543.Cohen D. Cancer drugs: high price, uncertain value. BMJ (Clin Res Ed). 2017;359:j4543., Cohen D. Cancer drugs: high price, uncertain value. BMJ (Clin Res Ed). 2017;359:j4543.
R. Kemp, V. Prasad (2017)
Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?BMC Medicine, 15
(2020)
( iTEN ) model
Jianya Zhou, Jing Zheng, Xiaochen Zhang, Jingyi Zhao, Yanping Zhu, Q. Shen, Yuehong Wang, K. Sun, Zeying Zhang, Zhijie Pan, Yihong Shen, Jianying Zhou (2018)
Crizotinib in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer versus chemotherapy as a first-line treatmentBMC Cancer, 18
(IARC. World Cancer Report 2014. Editors BW Stewart and CP Wild. Available at URL: http://www.searo.who.int/publications/bookstore/documents/9283204298/en/.)
IARC. World Cancer Report 2014. Editors BW Stewart and CP Wild. Available at URL: http://www.searo.who.int/publications/bookstore/documents/9283204298/en/.IARC. World Cancer Report 2014. Editors BW Stewart and CP Wild. Available at URL: http://www.searo.who.int/publications/bookstore/documents/9283204298/en/., IARC. World Cancer Report 2014. Editors BW Stewart and CP Wild. Available at URL: http://www.searo.who.int/publications/bookstore/documents/9283204298/en/.
X. Paoletti, L. Lewsley, G. Daniele, A. Cook, N. Yanaihara, A. Tinker, G. Kristensen, P. Ottevanger, G. Aravantinos, Austin Miller, I. Boere, R. Fruscio, A. Reyners, E. Pujade-Lauraine, A. Harkin, S. Pignata, T. Kagimura, S. Welch, J. Paul, E. Karamouza, R. Glasspool (2020)
Assessment of Progression-Free Survival as a Surrogate End Point of Overall Survival in First-Line Treatment of Ovarian CancerJAMA Network Open, 3
T. Yoshida, Y. Oya, Kosuke Tanaka, J. Shimizu, Y. Horio, H. Kuroda, Y. Sakao, T. Hida, Y. Yatabe (2016)
Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non-Small-Cell Lung Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34 28
Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
G. Adunlin, J. Cyrus, G. Dranitsaris (2015)
Correlation between progression-free survival and overall survival in metastatic breast cancer patients receiving anthracyclines, taxanes, or targeted therapies: a trial-level meta-analysisBreast Cancer Research and Treatment, 154
N. Duma, R. Santana-Davila, J. Molina (2019)
Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment.Mayo Clinic proceedings, 94 8
(IMS Institute for Healthcare Informatics. Global oncology trend report. A review of 2015 and outlook to 2020. June 2016. Available at URL: https://www.scribd.com/document/323179495/IMSH-Institute-Global-Oncology-Trend-2015-2020-Report.)
IMS Institute for Healthcare Informatics. Global oncology trend report. A review of 2015 and outlook to 2020. June 2016. Available at URL: https://www.scribd.com/document/323179495/IMSH-Institute-Global-Oncology-Trend-2015-2020-Report.IMS Institute for Healthcare Informatics. Global oncology trend report. A review of 2015 and outlook to 2020. June 2016. Available at URL: https://www.scribd.com/document/323179495/IMSH-Institute-Global-Oncology-Trend-2015-2020-Report., IMS Institute for Healthcare Informatics. Global oncology trend report. A review of 2015 and outlook to 2020. June 2016. Available at URL: https://www.scribd.com/document/323179495/IMSH-Institute-Global-Oncology-Trend-2015-2020-Report.
Shailja Shah, V. Kayamba, R. Peek, D. Heimburger (2019)
Cancer Control in Low- and Middle-Income Countries: Is It Time to Consider Screening?Journal of Global Oncology, 5
Y. Cha, H. Kim, H. Shim (2016)
Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variantsJournal of Translational Medicine, 14
(2015)
Evaluation of ASTM standard test method E 2177, 6 retroreflectivity of pavement markings in a condition of 7 wetness
M. Delgado-Rodríguez, M. Sillero-arenas (2017)
Systematic review and meta-analysis.Medicina intensiva, 42 7
I. Tsimafeyeu, F. Moiseenko, S. Orlov, E. Filippova, A. Belonogov, Aleksey Nebesnykh, Amir Khalimov, E. Karabina, V. Shikina, A. Abdelgafur, G. Statsenko, Irina Titova, Dmitry Isaichikov, Galina Makarnyaeva, Aleksey Mordovskiy, Oksana Barkovskaya, A. Smirnov, M. Gikalo, N. Savelov, D. Kosov, E. Imyanitov, I. Demidova, S. Tjulandin (2019)
Overall Survival of Patients With ALK-Positive Metastatic Non–Small-Cell Lung Cancer in the Russian Federation: Nationwide Cohort StudyJournal of Global Oncology, 5
(Elliott J, Bai Z, Hsieh S-C, Kelly SE, Chen L, Skidmore B, et al. ALK inhibitors for non-small cell lung cancer: a systematic review and network meta-analysis. PloS One. 2020;15(2):e0229179.)
Elliott J, Bai Z, Hsieh S-C, Kelly SE, Chen L, Skidmore B, et al. ALK inhibitors for non-small cell lung cancer: a systematic review and network meta-analysis. PloS One. 2020;15(2):e0229179.Elliott J, Bai Z, Hsieh S-C, Kelly SE, Chen L, Skidmore B, et al. ALK inhibitors for non-small cell lung cancer: a systematic review and network meta-analysis. PloS One. 2020;15(2):e0229179., Elliott J, Bai Z, Hsieh S-C, Kelly SE, Chen L, Skidmore B, et al. ALK inhibitors for non-small cell lung cancer: a systematic review and network meta-analysis. PloS One. 2020;15(2):e0229179.
D. Moher, A. Booth, L. Stewart (2014)
How to reduce unnecessary duplication: use PROSPEROBJOG: An International Journal of Obstetrics & Gynaecology, 121
D. Cohen (2017)
Cancer drugs: high price, uncertain valueThe BMJ, 359
Ying Jin, Yamei Chen, Xinmin Yu, Xun Shi (2018)
A real-world study of treatment patterns and survival outcome in advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer.Oncology letters, 15 6
(2018)
Final overall survival analysis from a study comparing first-line crizotinib versus chemotherapy in alk-mutation-positive non–small-cell lung cancerJ Clin Oncol, 36
E. Somers (1985)
International Agency for Research on Cancer.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 133 9
(2009)
The PRISMA statement for report- ing systematic reviews and meta-analyses of studies that evaluate health care interventions: explana- tion and elaboration
L. Kassem, K. Shohdy, S. Lasheen, O. Abdel-Rahman, Ahmad Ali, R. Abdel-Malek (2019)
Safety issues with the ALK inhibitors in the treatment of NSCLC: A systematic review.Critical reviews in oncology/hematology, 134
Yi-long Wu, Shun Lu, You Lu, Jianying Zhou, Yuankai Shi, V. Sriuranpong, J. Ho, C. Ong, C. Tsai, C. Chung, K. Wilner, Yiyun Tang, E. Masters, P. Selaru, T. Mok (2018)
Results of PROFILE 1029, a Phase III Comparison of First‐Line Crizotinib versus Chemotherapy in East Asian Patients with ALK‐Positive Advanced Non–Small Cell Lung CancerJournal of Thoracic Oncology, 13
P. Morgan, N. Woolacott, M. Biswas, T. Mebrahtu, M. Harden, R. Hodgson (2017)
Crizotinib for Untreated Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology AppraisalPharmacoEconomics, 35
(2019)
EvaluatePharma World Preview 2019, Outlook to 2024
(2019)
The global use of medicine in 2019 and outlook to 2023-forecasts and areas to watch
Tung Hoang, S. Myung, Thu-Thi Pham, Boyoung Park (2020)
Efficacy of Crizotinib, Ceritinib, and Alectinib in ALK-Positive Non-Small Cell Lung Cancer Treatment: A Meta-Analysis of Clinical TrialsCancers, 12
L. Stewart, D. Moher, P. Shekelle (2012)
Why prospective registration of systematic reviews makes senseSystematic Reviews, 1
K. Chalkidou, P. Marquez, P. Dhillon, Y. Teerawattananon, T. Anothaisintawee, C. Gadelha, R. Sullivan (2014)
Evidence-informed frameworks for cost-effective cancer care and prevention in low, middle, and high-income countries.The Lancet. Oncology, 15 3
(Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.)
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424., Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
D. Breadner, P. Blanchette, S. Shanmuganathan, R. Boldt, J. Raphael (2020)
Efficacy and safety of ALK inhibitors in ALK-rearranged non-small cell lung cancer: A systematic review and meta-analysis.Lung cancer, 144
(NICE. Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. Technology appraisal guidance [TA422]. 2016. Available at URL: https://www.nice.org.uk/guidance/ta422/chapter/1-Recommendations.)
NICE. Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. Technology appraisal guidance [TA422]. 2016. Available at URL: https://www.nice.org.uk/guidance/ta422/chapter/1-Recommendations.NICE. Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. Technology appraisal guidance [TA422]. 2016. Available at URL: https://www.nice.org.uk/guidance/ta422/chapter/1-Recommendations., NICE. Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. Technology appraisal guidance [TA422]. 2016. Available at URL: https://www.nice.org.uk/guidance/ta422/chapter/1-Recommendations.
T. Lancet (2018)
GLOBOCAN 2018: counting the toll of cancerThe Lancet, 392
(IQVIA. The global use of medicine in 2019 and outlook to 2023–forecasts and areas to watch. 2019. Available at URL: https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/the-global-use-of-medicine-in-2019-and-outlook-to-2023.pdf)
IQVIA. The global use of medicine in 2019 and outlook to 2023–forecasts and areas to watch. 2019. Available at URL: https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/the-global-use-of-medicine-in-2019-and-outlook-to-2023.pdfIQVIA. The global use of medicine in 2019 and outlook to 2023–forecasts and areas to watch. 2019. Available at URL: https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/the-global-use-of-medicine-in-2019-and-outlook-to-2023.pdf, IQVIA. The global use of medicine in 2019 and outlook to 2023–forecasts and areas to watch. 2019. Available at URL: https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/the-global-use-of-medicine-in-2019-and-outlook-to-2023.pdf
(Waters R, Urquhart L. EvaluatePharma® World Preview 2019, Outlook to 2024. 2019. Available at URL: https://info.evaluate.com/rs/607-YGS-364/images/EvaluatePharma_World_Preview_2019.pdf.)
Waters R, Urquhart L. EvaluatePharma® World Preview 2019, Outlook to 2024. 2019. Available at URL: https://info.evaluate.com/rs/607-YGS-364/images/EvaluatePharma_World_Preview_2019.pdf.Waters R, Urquhart L. EvaluatePharma® World Preview 2019, Outlook to 2024. 2019. Available at URL: https://info.evaluate.com/rs/607-YGS-364/images/EvaluatePharma_World_Preview_2019.pdf., Waters R, Urquhart L. EvaluatePharma® World Preview 2019, Outlook to 2024. 2019. Available at URL: https://info.evaluate.com/rs/607-YGS-364/images/EvaluatePharma_World_Preview_2019.pdf.
K. Duncan, R. Abudu, M. Cira, D. Pyle (2019)
Global Oncology Research and Training Collaborations Led by the National Cancer Institute (NCI)–Designated Cancer Centers: Results From the 2018 NCI/ASCO Global Oncology Survey of NCI-Designated Cancer CentersJournal of Global Oncology
Jesse Elliott, Zemin Bai, Shuching Hsieh, S. Kelly, Li Chen, B. Skidmore, Said Yousef, C. Zheng, D. Stewart, G. Wells (2020)
ALK inhibitors for non-small cell lung cancer: A systematic review and network meta-analysisPLoS ONE, 15
B. Solomon, T. Mok, Dong-Wan Kim, Yi-long Wu, K. Nakagawa, T. Mekhail, E. Felip, F. Cappuzzo, J. Paolini, T. Usari, S. Iyer, A. Reisman, K. Wilner, J. Tursi, F. Blackhall (2014)
First-line crizotinib versus chemotherapy in ALK-positive lung cancer.The New England journal of medicine, 371 23
(SMC. Crizotinib 200mg and 250mg hard capsules (Xalkori®) SMC No 1329/18. 2018. Available at URL: https://www.scottishmedicines.org.uk/media/3465/crizotinib-xalkori-final-may-2018-for-website.pdf.)
SMC. Crizotinib 200mg and 250mg hard capsules (Xalkori®) SMC No 1329/18. 2018. Available at URL: https://www.scottishmedicines.org.uk/media/3465/crizotinib-xalkori-final-may-2018-for-website.pdf.SMC. Crizotinib 200mg and 250mg hard capsules (Xalkori®) SMC No 1329/18. 2018. Available at URL: https://www.scottishmedicines.org.uk/media/3465/crizotinib-xalkori-final-may-2018-for-website.pdf., SMC. Crizotinib 200mg and 250mg hard capsules (Xalkori®) SMC No 1329/18. 2018. Available at URL: https://www.scottishmedicines.org.uk/media/3465/crizotinib-xalkori-final-may-2018-for-website.pdf.
Xiaoyan Li, Hua-lin Xu, Fang Gao, Xu Kang, Juan Zhang, Jin Zhao, Y. Lin, Xiaoqing Liu (2019)
克唑替尼治疗晚期或复发性ALK阳性非小细胞肺癌的疗效和安全性Chinese Journal of Lung Cancer, 22
Bo Zhang, Yanwei Zhang, Jianlin Xu, Xueyan Zhang, T. Chu, Shu-yuan Wang, J. Qian, R. Qiao, Jun Lu, Le-le Zhang, B. Han (2018)
Characteristics and Response to Crizotinib in ALK-Rearranged, Advanced Non-Adenocarcinoma, Non-Small Cell Lung Cancer (NA-NSCLC) Patients: a Retrospective Study and Literature ReviewTargeted Oncology, 13
Benjamin Solomon, B. Solomon, K. Wilner, A. Shaw (2013)
Current Status of Targeted Therapy for Anaplastic Lymphoma Kinase–Rearranged Non–Small Cell Lung CancerClinical Pharmacology & Therapeutics, 95
(Carlson JJ, Suh K, Orfanos P, Wong W. Cost effectiveness of alectinib vs. crizotinib in first-line anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. Pharm Econ. 2018;36(4):495–504.)
Carlson JJ, Suh K, Orfanos P, Wong W. Cost effectiveness of alectinib vs. crizotinib in first-line anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. Pharm Econ. 2018;36(4):495–504.Carlson JJ, Suh K, Orfanos P, Wong W. Cost effectiveness of alectinib vs. crizotinib in first-line anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. Pharm Econ. 2018;36(4):495–504., Carlson JJ, Suh K, Orfanos P, Wong W. Cost effectiveness of alectinib vs. crizotinib in first-line anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. Pharm Econ. 2018;36(4):495–504.
H. Vuong, Thu Nguyen, H. Nguyen, P. Nguyen, A. Ho, L. Hassell (2020)
Efficacy and Safety of Crizotinib in the Treatment of Advanced Non-Small-Cell Lung Cancer with ROS1 Rearrangement or MET Alteration: A Systematic Review and Meta-AnalysisTargeted Oncology, 15
Global oncology trend report. A review of 2015 and outlook to 2020
(WHO. International Agency for Research on Cancer. 2020. Available at URL: https://gco.iarc.fr/tomorrow/home.)
WHO. International Agency for Research on Cancer. 2020. Available at URL: https://gco.iarc.fr/tomorrow/home.WHO. International Agency for Research on Cancer. 2020. Available at URL: https://gco.iarc.fr/tomorrow/home., WHO. International Agency for Research on Cancer. 2020. Available at URL: https://gco.iarc.fr/tomorrow/home.
(Liberati A, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6(7). 10.1371/journal.pmed.1000100.)
Liberati A, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6(7). 10.1371/journal.pmed.1000100.Liberati A, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6(7). 10.1371/journal.pmed.1000100., Liberati A, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6(7). 10.1371/journal.pmed.1000100.
Gang Chen, Xi Chen, Yaxiong Zhang, Fang Yan, W. Fang, Yun-peng Yang, Shaodong Hong, Siyu Miao, Manli Wu, Xiaodan Huang, Youli Luo, Cong Zhou, Run Gong, Yan Huang, N. Zhou, Hongyun Zhao, Li Zhang (2017)
A large, single‐center, real‐world study of clinicopathological characteristics and treatment in advanced ALK‐positive non‐small‐cell lung cancerCancer Medicine, 6
Carolina Dias, B. Godman, L. Gargano, P. Azevedo, M. Garcia, Maurílio Cazarim, L. Pantuzza, Nelio Ribeiro-Junior, André Pereira, M. Borin, I. Zuppo, R. Iunes, T. Pippo, Renata Hauegen, C. Vassalo, T. Laba, S. Simoens, S. Marquez, C. Gómez, L. Voncina, G. Selke, L. Garattini, H. Kwon, J. Gulbinovič, Aneta Lipińska, Maciej Pomorski, L. McClure, Jurij Fürst, R. Gambogi, Carla Ortiz, V. Santos, D. Araújo, V. Araujo, F. Acurcio, J. Álvares-Teodoro, A. Guerra-Júnior (2020)
Integrative Review of Managed Entry Agreements: Chances and LimitationsPharmacoEconomics, 38
F. Bray, J. Ferlay, I. Soerjomataram, R. Siegel, Lindsey Torre, A. Jemal (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesCA: A Cancer Journal for Clinicians, 68
(2015)
Progression-free survival, post- progression survival, and tumor response as surro- gate markers for overall survival in patients with extensive small cell lung cancer
(Paoletti X, Lewsley LA, Daniele G, Cook A, Yanaihara N, Tinker A, et al. Assessment of progression-free survival as a surrogate end point of overall survival in first-line treatment of ovarian cancer: a systematic review and meta-analysis. JAMA Netw Open. 2020;3(1):e1918939.)
Paoletti X, Lewsley LA, Daniele G, Cook A, Yanaihara N, Tinker A, et al. Assessment of progression-free survival as a surrogate end point of overall survival in first-line treatment of ovarian cancer: a systematic review and meta-analysis. JAMA Netw Open. 2020;3(1):e1918939.Paoletti X, Lewsley LA, Daniele G, Cook A, Yanaihara N, Tinker A, et al. Assessment of progression-free survival as a surrogate end point of overall survival in first-line treatment of ovarian cancer: a systematic review and meta-analysis. JAMA Netw Open. 2020;3(1):e1918939., Paoletti X, Lewsley LA, Daniele G, Cook A, Yanaihara N, Tinker A, et al. Assessment of progression-free survival as a surrogate end point of overall survival in first-line treatment of ovarian cancer: a systematic review and meta-analysis. JAMA Netw Open. 2020;3(1):e1918939.
G. Dagenais, D. Leong, S. Rangarajan, F. Lanas, P. López-Jaramillo, Rajeev Gupta, R. Diaz, Á. Avezum, G.B.D.F. Oliveira, A. Wielgosz, Shameena Parambath, P. Mony, K. Alhabib, A. Temizhan, Noorhassim Ismail, J. Chifamba, K. Yeates, R. Khatib, O. Rahman, K. Zatońska, K. Kazmi, Li Wei, Li Wei, Jun Zhu, A. Rosengren, K. Vijayakumar, Manmeet Kaur, V. Mohan, A. Yusufali, R. Kelishadi, K. Teo, P. Joseph, S. Yusuf (2020)
Variations in common diseases, hospital admissions, and deaths in middle-aged adults in 21 countries from five continents (PURE): a prospective cohort studyThe Lancet, 395
S. Cui, Yizhuo Zhao, L. Dong, A. Gu, L. Xiong, J. Qian, Wei Zhang, Y. Niu, F. Pan, Liyan Jiang (2016)
Is there a progression‐free survival benefit of first‐line crizotinib versus standard chemotherapy and second‐line crizotinib in ALK‐positive advanced lung adenocarcinoma? A retrospective study of Chinese patientsCancer Medicine, 5
(Hoang T, Myung SK, Pham TT, Park B. Efficacy of crizotinib, ceritinib, and alectinib in ALK-positive non-small cell lung cancer treatment: a meta-analysis of clinical trials. Cancers (Basel). 2020;12(3). 10.3390/cancers12030526)
Hoang T, Myung SK, Pham TT, Park B. Efficacy of crizotinib, ceritinib, and alectinib in ALK-positive non-small cell lung cancer treatment: a meta-analysis of clinical trials. Cancers (Basel). 2020;12(3). 10.3390/cancers12030526Hoang T, Myung SK, Pham TT, Park B. Efficacy of crizotinib, ceritinib, and alectinib in ALK-positive non-small cell lung cancer treatment: a meta-analysis of clinical trials. Cancers (Basel). 2020;12(3). 10.3390/cancers12030526, Hoang T, Myung SK, Pham TT, Park B. Efficacy of crizotinib, ceritinib, and alectinib in ALK-positive non-small cell lung cancer treatment: a meta-analysis of clinical trials. Cancers (Basel). 2020;12(3). 10.3390/cancers12030526
Junsheng Fan, Tszhei Fong, Zengfei Xia, Jian Zhang, P. Luo (2018)
The efficacy and safety of ALK inhibitors in the treatment of ALK‐positive non‐small cell lung cancer: A network meta‐analysisCancer Medicine, 7
B. Solomon, Dong-Wan Kim, Yi-long Wu, K. Nakagawa, T. Mekhail, E. Felip, F. Cappuzzo, J. Paolini, T. Usari, Yiyun Tang, K. Wilner, F. Blackhall, T. Mok (2018)
Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib With Chemotherapy: Results From PROFILE 1014Journal of Clinical Oncology
Muhammad Khan, Jie Lin, Guixiang Liao, Yunhong Tian, Yingying Liang, Rong Li, Mengzhong Liu, Yawei Yuan (2019)
ALK Inhibitors in the Treatment of ALK Positive NSCLCFrontiers in Oncology, 8
(Moldaver D, et al. Development, validation and results from the impact of treatment evolution in non-small cell lung cancer (iTEN) model. Lung Cancer. 2020;139(2019): 185–194. 10.1016/j.lungcan.2019.10.019.)
Moldaver D, et al. Development, validation and results from the impact of treatment evolution in non-small cell lung cancer (iTEN) model. Lung Cancer. 2020;139(2019): 185–194. 10.1016/j.lungcan.2019.10.019.Moldaver D, et al. Development, validation and results from the impact of treatment evolution in non-small cell lung cancer (iTEN) model. Lung Cancer. 2020;139(2019): 185–194. 10.1016/j.lungcan.2019.10.019., Moldaver D, et al. Development, validation and results from the impact of treatment evolution in non-small cell lung cancer (iTEN) model. Lung Cancer. 2020;139(2019): 185–194. 10.1016/j.lungcan.2019.10.019.
Min-Wen Zheng (2016)
Classification and Pathology of Lung Cancer.Surgical oncology clinics of North America, 25 3
IntroductionLung cancer is the most frequently diagnosed type of cancer and the main cause of death from malignant neoplasms worldwide. One of the most recent discoveries in the context of non-small cell lung cancer (NSCLC) was the mutation of the anaplastic lymphoma kinase receptor (ALK). This genetic alteration is found in approximately 2–5% of NSCLC patients, and crizotinib was the first targeted therapy discovered for its first-line treatment.ObjectiveTo conduct a systematic review and meta-analysis to estimate the magnitude of the overall survival (OS) and progression-free survival (PFS) from using crizotinib as treatment compared to traditional chemotherapy to guide future decision making.MethodsPRISMA and Cochrane recommendations were followed using the findings based on studies published in the main international electronic databases. Selection criteria included the following: randomized clinical trials (RCT) or cohort studies that had assessed the efficacy and effectiveness of crizotinib as monotherapy in patients with NSCLC with ALK fusions.ResultsFrom 2504 publications identified in the literature, only eight publications referring to seven studies met the selection criteria, with high heterogeneity identified between the studies. Overall, there was a significant gain in PFS (HR 0.38; 95% CI 0.30–0.49; p < 0.00001); however, there was no significant gain in OS (HR 0.68; 95% CI 0.43–1.08; p = 0.10).ConclusionThe study highlighted and confirmed that treatment with crizotinib led to clinical improvement in PFS among patients with advanced NSCLC with ALK fusion, as previously reported. However, there was no increase in overall survival in patients with NSCLC with genetic alterations of ALK. This must be considered when reviewing and funding treatments for NSCLC patients with this mutation.
Oncology and Therapy – Springer Journals
Published: Dec 1, 2021
Keywords: Anaplastic lymphoma kinase; Crizotinib; Effectiveness; Efficacy; Lung cancer; Systematic review
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.